Volume 7, Number 2—April 2001
THEME ISSUE
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
Introduction
Emergence of Vancomycin-Resistant Enterococci
Louis B. Rice
Table 2
Antibiotic treatment and persistence of high-level colonization with vancomycin and ampicillin-resistant Enterococcus faecium C68 (47)
| Approximate log10 CFU VRE/g stoola | |||||
|---|---|---|---|---|---|
| Day 0 |
Day 4-5 |
Day 9-10 |
Day 14-15 |
Day 19-20 |
|
| Saline | 9.5 | 8.3 | 6 | 3.8 | 3.5 |
| Vancomycin (SQ) | >9 | >9 | >9 | >9 | >9 |
| Vancomycin (oral) | >9 | >9 | >9 | >9 | >9 |
| Antibiotics with potent antianaerobic activity | |||||
| Piperacillin-tazobactam | >9 | >9 | >9 | >9 | >9 |
| Ticarcillin-clavulanic acid | >9 | >9 | >9 | >9 | >9 |
| Clindamycin | >9 | >9 | >9 | >9 | >9 |
| Cefotetan | >9 | >9 | 8.8 | 7.8 | 8 |
| Metronidazole | >9 | >9 | >9 | >9 | >9 |
| Ampicillin | >9 | >9 | 8 | 7.2 | 7 |
| Ampicillin-sulbactam | >9 | >9 | >9 | 7.8 | 7.7 |
| Antibiotic withs relatively poor activity against anaerobic bacteria | |||||
| Cefepime | >9 | >9 | 6.2 | 5 | 4.8 |
| Ceftriaxone | >9 | 8.8 | 8.4 | 7.2 | 6 |
| Aztreonam | >9 | 9 | 4.3 | 4.2 | 3.8 |
| Ciprofloxacin | >9 | 8.8 | 6 | 5.2 | 5 |
aVRE = vancomycin-resistant enterococci.; SQ = subcutaneous
